Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Project Profile
Share
QR code
A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Sponsoring Agencies:
NATL INST OF HLTH NC, NRG ONCOLOGY FOU
Investigator
Thomas George
Associateprofessor - Physician
Md-Hematology/Oncology | College-Medicine
352-273-8008
tgeorge@ufl.edu
Funding
Award
$2,450.00
Begin Date
September 16, 2014
End Date
February 28, 2019
Research Terms
Clinical Oncology
Cancer Treatment
Drug Therapy
Cancer
Digestive System Diseases
Industries
Health Care
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
